Keros Therapeutics, Inc. — Director's Dealing 2021

Dec 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Keros Therapeutics, Inc. (KROS)
CIK: 0001664710
Period of Report: 2021-12-01

Reporting Person: Knowles Julius (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-01	Common Stock	S	4243	$53.48	Disposed	395014	Indirect
2021-12-01	Common Stock	S	2766	$53.48	Disposed	267580	Indirect
2021-12-01	Common Stock	S	5168	$54.67	Disposed	389846	Indirect
2021-12-01	Common Stock	S	3372	$54.67	Disposed	264208	Indirect
2021-12-01	Common Stock	S	2528	$55.71	Disposed	387318	Indirect
2021-12-01	Common Stock	S	1649	$55.71	Disposed	262559	Indirect
2021-12-01	Common Stock	S	1566	$56.27	Disposed	385752	Indirect
2021-12-01	Common Stock	S	1021	$56.27	Disposed	261538	Indirect
2021-12-02	Common Stock	S	79	$51.99	Disposed	385673	Indirect
2021-12-02	Common Stock	S	52	$52.00	Disposed	261486	Indirect
2021-12-02	Common Stock	S	6372	$53.17	Disposed	379301	Indirect
2021-12-02	Common Stock	S	4155	$53.17	Disposed	257331	Indirect
2021-12-02	Common Stock	S	8747	$53.86	Disposed	370554	Indirect
2021-12-02	Common Stock	S	5705	$53.86	Disposed	251626	Indirect
2021-12-02	Common Stock	S	138	$54.67	Disposed	370416	Indirect
2021-12-02	Common Stock	S	90	$54.67	Disposed	251536	Indirect

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.04 to $54.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8), (9), (10) and (11).

F3: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I.

F4: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.055 to $55.05 inclusive.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.055 to $56.05 inclusive.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.06 to $57.02 inclusive.

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.58 to $52.57 inclusive.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.61 to $53.605 inclusive.

F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.625 to $54.43 inclusive.

F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.665 to $54.69 inclusive.